Pacific Biosciences of California

Pacific Biosciences of California

PACB · NASDAQ · Healthcare / Medical Devices

1.96USD-0.01 (-0.51%)

Price History

Full chart

Market Stats

Previous Close1.97
Open1.99
Day Range1.84 – 2.00
52-Week Range1.07 – 2.73
Volume7.02M
Market Cap503.55M
P/E (TTM)0.00
Forward P/E0.00
EPS-0.42
Dividend Yield0.00%
Beta2.31
50-Day Avg1.34
200-Day Avg1.58

About

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solutions to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-read sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, the company provides Revio, Vega, and Sequel instruments which conduct, monitor, and analyze single-molecule biochemical reactions on SMRT cell microchips; short-read sequencing; and onso instrument. It serves academic and governmental research institutions, commercial testing and service laboratories, genome centers, public health labs, hospitals and clinical research institutes, contract research organizations, pharmaceutical companies, and agricultural companies. The company markets its products through a sales force and distribution partners in Australia, certain parts of Asia, Europe, the Middle East, Africa, Central America, and South America. It has a collaboration with DNAstack Inc. to provide federated dataset of HiFi whole genome sequencing data. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.

Company Details

  • SectorHealthcare
  • IndustryMedical Devices
  • CEOMr. Mark Van Oene Ph.D.
  • Employees485
  • Headquarters1305 O?Brien Drive, Menlo Park, CA, United States, 94025, USA
  • Websitehttps://www.pacb.com

Leadership

  • Mr. Mark Van Oene Ph.D.CEO, President & Director · b. 1973
  • Mr. James R. Gibson IICFO & Principal Accounting Officer · b. 1970
  • Mr. Christian O. Henry M.B.A.Senior Business Advisor & Director · b. 1968
  • Dr. Stephen Turner Ph.D.Co-Founder · b. 1968
  • Dr. Brett Atkins J.D., Ph.D.General Counsel & Corporate Secretary
  • Ms. Natalie WelchChief People Officer

Financials

Income Statement

Currency: USD2007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue2.16M901.00K135.00K1.67M33.86M25.98M28.18M60.59M92.78M90.71M93.47M78.63M90.89M78.89M130.51M128.30M200.52M154.01M160.00M
Growth (%)--58.34%-85.02%+1140.00%+1922.88%-23.27%+8.46%+115.02%+53.12%-2.23%+3.04%-15.88%+15.60%-13.20%+65.43%-1.69%+56.29%-23.19%+3.89%
Cost of Revenue-42.72M84.10M136.75M20.83M25.04M21.76M37.19M39.33M46.55M58.81M53.53M56.31M46.33M71.65M79.27M147.74M116.73M109.33M
Gross Profit2.16M901.00K135.00K1.67M13.03M940.00K6.42M23.40M53.45M44.16M34.66M25.10M34.58M32.57M58.86M49.03M52.78M37.28M50.67M
Gross Margin100.00%100.00%100.00%100.00%38.49%3.62%22.78%38.62%57.61%48.68%37.08%31.92%38.04%41.28%45.10%38.22%26.32%24.21%31.67%
Operating Expense25.55M45.71M88.20M141.91M122.79M95.28M83.96M86.26M82.58M115.40M124.44M126.08M135.12M136.95M269.30M356.23M387.25M511.60M608.24M
Operating Income-23.39M-44.81M-88.07M-140.23M-109.76M-94.34M-77.54M-62.85M-29.13M-71.24M-89.78M-100.99M-100.55M-104.39M-210.44M-307.20M-334.47M-474.31M-557.56M
Operating Margin-1081.41%-4973.25%-65237.04%-8377.18%-324.12%-363.08%-275.16%-103.73%-31.40%-78.54%-96.06%-128.44%-110.62%-132.31%-161.24%-239.43%-166.80%-307.97%-348.46%
EBITDA-21.81M-41.82M-83.97M-135.01M-103.28M-87.52M-71.17M-59.11M-25.09M-67.27M-80.83M-92.92M-71.58M38.97M-250.76M-282.24M-271.13M-242.77M-34.20M
EBITDA Margin-1008.51%-4641.73%-62197.04%-8064.87%-305.01%-336.82%-252.54%-97.55%-27.05%-74.15%-86.47%-118.18%-78.75%49.40%-192.13%-219.98%-135.21%-157.63%-21.37%
Net Income-21.52M-43.75M-87.70M-140.17M-109.39M-94.47M-79.29M-66.16M-31.70M-74.38M-92.19M-102.56M-84.13M29.40M-181.22M-314.25M-306.74M-309.85M-546.38M
Net Income Margin-994.82%-4856.16%-64965.19%-8373.12%-323.03%-363.56%-281.37%-109.19%-34.16%-81.99%-98.63%-130.44%-92.57%37.27%-138.85%-244.92%-152.97%-201.18%-341.47%
R&D19.22M38.00M75.88M111.82M76.08M47.62M45.22M48.23M60.44M67.62M65.32M62.59M59.63M64.15M112.90M193.00M187.17M134.92M97.31M
R&D as % of Total Revenue888.40%4217.20%56206.67%6679.87%224.67%183.29%160.45%79.60%65.14%74.54%69.89%79.61%65.61%81.32%86.50%150.42%93.34%87.60%60.81%
Interest Expense0000287.00K274.00K2.48M2.83M2.93M3.23M2.92M2.42M2.61M267.00K12.53M14.69M14.34M13.41M6.95M
Interest Expense % of Total Revenue0.00%0.00%0.00%0.00%0.85%1.05%8.79%4.67%3.15%3.57%3.13%3.08%2.87%0.34%9.60%11.45%7.15%8.71%4.35%

Balance Sheet

Currency: USD2007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets-113.11M101.10M305.75M218.32M129.68M136.19M124.52M131.11M137.88M144.08M170.28M147.99M413.98M2.01B1.77B1.75B1.26B784.08M
Total Liabilities-206.50M278.22M25.88M26.85M20.30M67.00M69.57M57.57M53.22M57.98M56.21M93.07M78.49M1.22B1.20B1.04B753.85M778.73M
Total Equity--93.39M-177.12M279.87M191.46M109.38M69.18M54.95M73.54M84.67M86.10M114.06M54.92M335.49M790.99M562.90M701.30M506.59M5.35M
Cash-78.46M89.23M147.65M58.87M46.54M26.36M36.45M82.27M16.77M62.87M18.84M29.63M81.61M460.73M325.09M179.91M55.37M63.71M
Total Debt-1.30M-3.04M2.93M2.79M15.96M25.57M17.03M32.71M19.93M20.95M61.67M42.00M955.36M948.48M933.93M672.43M759.91M
Net Debt--77.16M-89.23M-144.61M-55.94M-43.75M-10.40M-22.32M-67.32M-659.00K-49.24M-4.18M32.05M-39.61M494.63M623.39M754.02M617.06M696.20M

Cash Flow

Currency: USD2007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-16.73M-38.30M-74.84M-122.00M-102.97M-76.82M-29.83M-51.47M-47.89M-67.93M-67.52M-66.43M-78.31M19.50M-111.18M-263.21M-266.55M-206.06M-111.21M
Investing Cash Flow-18.34M-10.39M18.59M-138.25M6.45M61.79M-33.12M19.56M8.61M-14.86M-1.55M-38.41M62.05M-219.32M-678.53M116.08M4.60M124.00M115.45M
Financing Cash Flow-225.00K119.93M67.01M318.66M7.74M2.71M42.77M41.99M36.46M65.93M68.81M107.18M26.55M251.84M1.17B9.62M116.27M-42.99M3.43M
Capital Expenditure3.05M5.70M5.18M5.26M9.28M1.70M909.00K1.61M3.01M8.21M10.43M1.85M2.84M1.04M5.93M16.93M8.84M6.19M2.71M
Free Cash Flow-19.78M-44.01M-80.02M-127.25M-112.26M-78.53M-30.74M-53.08M-50.90M-76.14M-77.95M-68.28M-81.15M18.46M-117.11M-280.14M-275.39M-212.25M-113.92M
Dividends Paid----0000000--------
FCF to OCF118.22%114.89%106.92%104.31%109.02%102.22%103.05%103.13%106.28%112.08%115.45%102.79%103.62%94.67%105.33%106.43%103.32%103.00%102.44%
Dividend Paid to FCF----0.00%0.00%0.00%0.00%0.00%0.00%0.00%--------

Earnings

Report DateNov 30, 2010Feb 15, 2011Apr 27, 2011Aug 4, 2011Oct 27, 2011Feb 7, 2012May 1, 2012Jul 26, 2012Oct 25, 2012Feb 5, 2013Apr 23, 2013Aug 1, 2013Oct 22, 2013Feb 4, 2014Apr 30, 2014Jul 24, 2014Oct 23, 2014Feb 3, 2015May 5, 2015Aug 5, 2015Oct 22, 2015Feb 3, 2016Apr 21, 2016Aug 4, 2016Nov 2, 2016Feb 2, 2017Apr 26, 2017Aug 2, 2017Nov 2, 2017Feb 1, 2018May 2, 2018Aug 2, 2018Nov 1, 2018Feb 11, 2019May 3, 2019Aug 6, 2019Nov 7, 2019Feb 6, 2020May 6, 2020Aug 3, 2020Nov 2, 2020Feb 10, 2021Apr 29, 2021Aug 3, 2021Nov 2, 2021Feb 15, 2022May 4, 2022Aug 3, 2022Nov 7, 2022Feb 16, 2023May 2, 2023Aug 2, 2023Oct 30, 2023Feb 15, 2024May 9, 2024Aug 7, 2024Nov 7, 2024Feb 13, 2025May 8, 2025Aug 7, 2025Nov 5, 2025Feb 12, 2026May 7, 2026Aug 5, 2026Nov 4, 2026
EPS Estimate--0.91-0.67-0.63-0.57-0.50-0.47-0.46-0.42-0.37-0.37-0.34-0.29-0.27-0.27-0.26-0.12-0.25-0.26-0.14-0.27-0.03-0.24-0.22-0.20-0.23-0.23-0.24-0.19-0.20-0.19-0.17-0.15-0.13-0.16-0.14-0.15-0.14-0.15-0.18-0.13-0.12-0.31-0.21-0.24-0.29-0.32-0.34-0.33-0.36-0.33-0.31-0.29-0.28-0.26-0.22-0.21-0.17-0.19-0.18-0.16-0.13-0.13-0.14-0.13
EPS Actual-39.70-0.97-0.66-0.42-0.45-0.33-0.47-0.40-0.41-0.39-0.37-0.33-0.31-0.26-0.28-0.27-0.13-0.26-0.27-0.16-0.28-0.02-0.23-0.21-0.19-0.21-0.26-0.26-0.19-0.18-0.20-0.17-0.19-0.21-0.16-0.14-0.17-0.11-0.21-0.15-0.14-0.12-0.45-0.21-0.23-0.30-0.37-0.34-0.32-0.37-0.31-0.26-0.27-0.27-0.26-0.20-0.17-0.20-0.15-0.13-0.12-0.12-0.12-0.14-
Surprise--6.59%1.49%33.33%21.05%34.00%0.00%13.04%2.38%-5.41%0.00%2.94%-6.90%3.70%-3.70%-3.85%-8.33%-4.00%-3.85%-14.29%-3.70%33.33%4.17%4.55%5.00%8.70%-13.04%-8.33%0.00%10.00%-5.26%0.00%-26.67%-61.54%0.00%0.00%-13.33%21.43%-40.00%16.67%-7.69%0.00%-45.16%0.00%4.17%-3.45%-15.63%0.00%3.03%-2.78%6.06%16.13%6.90%3.57%0.00%9.09%19.05%-17.65%21.05%27.78%25.00%7.69%7.69%0.00%-
Timing--After-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hours-

Key Statistics & Ratios

Market Cap503.55M
Enterprise Value904.42M
Trailing P/E0.00
Forward P/E0.00
PEG Ratio-0.17
Price / Sales3.16
Price / Book170.66
EPS-0.42
Book Value-0.107
Revenue (TTM)159.27M
Gross Profit (TTM)46.86M
EBITDA199.18M
Profit Margin-82.49%
Operating Margin-114.36%
Return on Equity-929.32%
Return on Assets-14.07%
Shares Outstanding310.83M
Shares Float304.01M
Beta2.31
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Buy
Based on 14 analystsTarget 2.16
  • Strong Buy
    5
  • Buy
    1
  • Hold
    8

Ownership Breakdown

Institutions
55.52%
Insiders
8.91%
Retail / Other
35.57%

Top Institutional Holders

  • ARK Investment Management LLC
    36.27M11.67%
  • BlackRock Inc
    25.27M8.13%
  • SoftBank Group Corp
    20.45M6.58%
  • Vanguard Capital Management, LLC
    12.78M4.11%
  • Geode Capital Management, LLC
    6.98M2.24%
  • State Street Corp
    6.12M1.97%
  • Sumitomo Mitsui Trust Group Inc
    6.01M1.93%
  • Amova Asset Management Americas, Inc
    6.01M1.93%
  • Two Sigma Investments LLC
    4.24M1.36%
  • D. E. Shaw & Co LP
    4.21M1.35%
  • Millennium Management LLC
    3.96M1.27%
  • Nuveen, LLC
    2.95M0.95%
  • Vanguard Portfolio Management, LLC
    2.87M0.92%
  • Citadel Advisors Llc
    2.85M0.92%

Top Fund Holders

  • ARK Innovation ETF
    12.34M3.97%
  • ARK Genomic Revolution ETF
    11.26M3.62%
  • Vanguard MStar Total Stk Mkt Idx Invest
    9.54M3.07%
  • iShares Russell 2000 ETF
    7.24M2.33%
  • Amova ARK Pstv Chg Innovt P JPY Acc
    3.19M1.03%
  • Fidelity Small Cap Index
    3.05M0.98%